Federal Register #DEA-1644

DEA Notice of Intent: Temporary Placement of Mitragynine Pseudoindoxyl, MGM15, and MGM16 in Schedule I

This notice from the Drug Enforcement Administration (DEA) announces the intent to temporarily place three potent synthetic opioids into Schedule I of the Controlled Substances Act. - Government Buyer: - Department of Justice, Drug Enforcement Administration (DEA) - Substances to be Scheduled (Not OEM products, but chemical compounds): - Mitragynine pseudoindoxyl (part number: mitragynine pseudoindoxyl) - MGM15 (dihydro-7-hydroxymitragynine; part number: MGM15) - MGM16 (9-fluoro derivative of 7-hydroxymitragynine; part number: MGM16) - Products/Forms Mentioned: - Marketed in flavored chewable tablets and liquid shots - Notable Requirements: - All isomers, esters, ethers, salts, and related forms of these substances are included - Regulatory controls and sanctions will apply to manufacture, distribution, possession, import/export, and research - Action is based on high opioid potency, strong mu-opioid receptor affinity, and significant public health risks - No OEMs or commercial vendors are named, as this is a regulatory action, not a procurement - No products or services are being solicited; this is a notice to impose regulatory controls

Description

The Drug Enforcement Administration (DEA) intends to issue a temporary order to place three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16) in Schedule I of the Controlled Substances Act. This temporary scheduling will impose regulatory controls and sanctions applicable to Schedule I substances on persons who handle these substances, including manufacturing, distributing, importing, exporting, researching, or possessing them. The action is necessary to avoid an imminent hazard to public safety due to the substances' high opioid potency and abuse potential. The temporary scheduling order will take effect on or after August 5, 2026.

View original listing